Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 6—June 2009


Serologic Screening for Neospora caninum, France

Cite This Article


Highlight and copy the desired format.

EID Robert-Gangneux F, Klein F. Serologic Screening for Neospora caninum, France. Emerg Infect Dis. 2009;15(6):987-988.
AMA Robert-Gangneux F, Klein F. Serologic Screening for Neospora caninum, France. Emerging Infectious Diseases. 2009;15(6):987-988. doi:10.3201/eid1506.081414.
APA Robert-Gangneux, F., & Klein, F. (2009). Serologic Screening for Neospora caninum, France. Emerging Infectious Diseases, 15(6), 987-988.

To the Editor: In the June 2008 issue of Emerging Infectious Diseases, McCann et al. (1) reported on serologic screening for Neospora caninum antibodies and reported a lack of serologic evidence for Neospora infection in humans in England, where prevalence of infection with the closely related parasite Toxoplasma gondii also is low. Only limited data are available on human exposure to Neospora. We investigated the seroprevalence of N. caninum in humans in France, where Toxoplasma spp. seroprevalence is high.

Our study comprised 500 serum samples from healthy women, followed at the Cochin–Port Royal University Hospital in 1997 within the framework of toxoplasmosis surveillance during pregnancy, and 400 serum samples from HIV-infected patients. All serum samples were submitted to anti-Toxoplasma antibody testing by using indirect immunofluorescence (IIF; Toxo-spot IFI; bioMérieux, Marcy l’Etoile, France) and ELISA (Platelia Toxo IgG and IgM; BioRad, Hercules, CA, USA). An in-house microplate IIF test previously validated in cattle was used for simultaneous detection of anti-Neospora and anti-Toxoplasma immunoglobulin (Ig) G on the same microplate. All samples were screened at dilutions of 1:20 and 1:80, as is usually done in anti-Toxoplasma IIF assays in humans. Correlation between the anti-Toxoplasma IIF commercial test and in-house IIF was excellent (kappa coefficient = 0.98) and allowed us to compare the antibody titers against both parasites. Forty (8%) samples from immunocompetent persons and 21 (4%) from immunocompromised persons yielded a weak fluorescence when diluted 1:20. All but 4 had significant titers of anti-Toxoplasma IgG (>200 IU/mL in 77% of cases), which suggests low-level cross-reactions. Whereas titers of >200 and >320 are considered sufficient to diagnose neosporosis in dogs and cattle, respectively (2), positivity threshold was difficult to resolve in the absence of a positive human control. We decided on a positivity threshold of 1:80, which is similar to the threshold defined by others in further studies using an indirect fluorescence antibody test in humans (3,4). None of the 500 samples from immunocompetent persons were positive for Neospora antibodies when assessed at a dilution of 1:80. Within the group of immunocompromised persons, 3 were positive for Neospora antibodies at a titer of 80, and 1 was positive at a titer of 160. Three of these 4 HIV-infected patients had high titers of anti-Toxoplasma IgG (>2,000 IU/mL), suggesting Toxoplasma serologic reactivation. We found no evidence of Neospora infection or exposure in immunocompetent persons but could not exclude possible Neospora infection associated with Toxoplasma infection or reactivation in immunocompromised persons.

Taken together, our data agree with data from other studies conducted in European countries (1,5), which suggest that neosporosis in healthy humans is unlikely. However, the Neospora spp. seropositivity of some HIV-infected patients, although weak compared with the level of seropositivity in cattle or dogs, could suggest circulation of the parasite within immunocompromised hosts, a hypothesis supported by Lobato et al. (3). However, our observation of a strong serologic reactivation against T. gondii in 3 of 4 patients with anti-Neospora titers >80 mostly favors cross-reactivity involving homologous antigens of both parasites and nonspecific antibody binding from polyclonal stimulation of the immune system. Finally, one should keep in mind that the positive predictive value of a serologic test used in screening in low-prevalence populations is low. Large-scale studies are needed to more precisely determine the potential role of this parasite in immunodeficient humans and to isolate the parasite or detect Neospora DNA in such patients.

Florence Robert-GangneuxComments to Author  and Frédéric Klein

Author affiliations: Université Rennes 1, Rennes, France (F. Robert-Gangneux); Laboratoire Départemental de l’Orne, Alençon, France (F. Klein)


  1. McCann CM, Vyse AJ, Salmon RL, Thomas D, Williams DJ, McGarry JW, Lack of serologic evidence of Neospora caninum in humans, England. Emerg Infect Dis. 2008;14:97880. DOIPubMed
  2. Dubey JP, Lindsay DS. A review of Neospora caninum and neosporosis. Vet Parasitol. 1996;67:159. DOIPubMed
  3. Lobato J, Silva DA, Mineo TW, Amaral JD, Segundo GR, Costa-Cruz JM, Detection of immunoglobulin G antibodies to Neospora caninum in humans: high seropositivity rates in patients who are infected by human immunodeficiency virus or have neurological disorders. Clin Vaccine Immunol. 2006;13:849. DOIPubMed
  4. Tranas J, Heinzen RA, Weiss LM, McAllister MM. Serological evidence of human infection with the protozoan Neospora caninum. Clin Diagn Lab Immunol. 1999;6:7657.PubMed
  5. Petersen E, Lebech M, Jensen L, Lind P, Rask M, Bagger P, Neospora caninum infection and repeated abortions in humans. Emerg Infect Dis. 1999;5:27880.PubMed
Cite This Article

DOI: 10.3201/eid1506.081414

Related Links

Table of Contents – Volume 15, Number 6—June 2009


Please use the form below to submit correspondence to the authors or contact them at the following address:

Florence Robert-Gangneux, Laboratoire de Parasitologie–Mycologie, Centre Hospitalier et Universitaire de Rennes et Faculté de Médecine, Université Rennes 1, 2 Avenue Pr Léon Bernard, 35043 Rennes CEDEX, France

character(s) remaining.

Comment submitted successfully, thank you for your feedback.